Predicting Liver‐Related Outcomes in People With Nonalcoholic Fatty Liver Disease: The Prognostic Value of Noninvasive Fibrosis Tests

Amy L. Johnson, Kelly L. Hayward, Preya Patel, Leigh U. Horsfall, Alvin Ee Zhiun Cheah, Katharine M. Irvine, Anthony W. Russell, Katherine A. Stuart, Sue Williams, Gunter Hartel, Patricia C. Valery, Elizabeth E. Powell – 14 November 2021 – It remains unclear whether screening for advanced fibrosis in the community can identify the subgroup of people with nonalcoholic fatty liver disease (NAFLD) at higher risk for development of liver‐related complications.

Quality measures in HCC care by the Practice Metrics Committee of the American Association for the Study of Liver Diseases

Sumeet K. Asrani, Marwan S. Ghabril, Alexander Kuo, Raphael B. Merriman, Timothy Morgan, Neehar D. Parikh, Nadia Ovchinsky, Fasiha Kanwal, Michael L. Volk, Chanda Ho, Marina Serper, Shivang Mehta, Vatche Agopian, Roniel Cabrera, Victoria Chernyak, Hashem B. El‐Serag, Julie Heimbach, George N. Ioannou, David Kaplan, Jorge Marrero, Neil Mehta, Amit Singal, Riad Salem, Tamar Taddei, Anne M. Walling, Elliot B. Tapper – 14 November 2021 – The burden of HCC is substantial.

Immunogenicity and Adverse Effects of the 2‐Dose BNT162b2 Messenger RNA Vaccine Among Liver Transplantation Recipients

Yana Davidov, Keren Tsaraf, Oranit Cohen‐Ezra, Mariya Likhter, Gil Ben Yakov, Itzchak Levy, Einav G. Levin, Yaniv Lustig, Orna Mor, Galia Rahav, Ziv Ben Ari – 11 November 2021 – The BNT162b2 messenger RNA (mRNA) vaccine against severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) has been shown to be safe and effective in immunocompetent patients. The safety and efficacy of this vaccine in liver transplantation (LT) recipients is still under evaluation. The objective of this study was to assess the safety and efficacy of the BNT162b2 vaccine among transplant recipients.

Tripartite motif‐containing protein 11 promotes hepatocellular carcinogenesis through ubiquitin‐proteasome–mediated degradation of pleckstrin homology domain leucine‐rich repeats protein phosphatase 1

Juan Yang, Jianming Ye, Tengfei Ma, Fangfang Tang, Li Huang, Zhen Liu, Song Tian, Xu Cheng, Li Zhang, Zhenli Guo, Fuping Tu, Miao He, Xueming Xu, Xiaojuan Lu, Yanyang Wu, Xiaoli Zeng, Jiahua Zou, Xiangcai Wang, Weijie Peng, Peng Zhang – 11 November 2021

A GLP‐1/GLP‐2 receptor dual agonist to treat NASH: Targeting the gut‐liver axis and microbiome

Eun Ran Kim, Jeong Su Park, Jin Hee Kim, Ji Young Oh, In Jeong Oh, Da Hyun Choi, Yu seol Lee, I. Seul Park, SeungWon Kim, Da Hyun Lee, Jae Hee Cheon, Jin‐Woo Bae, Minyoung Lee, Jin Won Cho, In Bok An, Eun Joo Nam, Sang‐In Yang, Myung‐Shik Lee, Soo Han Bae, Yong‐ho Lee – 11 November 2021

Subscribe to